Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revised EMA Guideline On First-In-Human Trials Addresses Dosing And Complex Protocols

Executive Summary

The European Medicines Agency has updated its 2007 guideline on the strategies drug sponsors should apply to identify and mitigate risks in first-in-human trials to provide additional advice on dosing issues and the use of integrated protocols, among other things. The revised guideline will apply from February 2018.

You may also be interested in...

Brexit: How The UK MHRA And Its EU Roles Could Be Affected

The UK MHRA’s latest annual report reveals how much income the agency receives for activities it carries out on behalf of the European Medicines Agency, and looks among other things at how the MHRA should address the challenges raised by Brexit.

EMA First-In-Human Trial Proposals Focus On Dosing, Non-Clinical Data, Study Design

The European Medicines Agency has put out for consultation a draft revised guideline intended to minimize the risks involved with running first-in-human and other early clinical trials, taking into account the lessons learnt from the French Phase I trial tragedy at the beginning of 2016.

Better Risk Assessment And Dose Determination Key To EMA's Plans For Updated Phase I Trial Guideline

Proposed revisions to the European Medicines Agency's guideline on first-in-human studies are intended to help identify and reduce the risks to study participants by making better use of non-clinical data in areas like the choice of the therapeutic dose, the dose escalation strategy, and the criteria for stopping a trial.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts